NovoCure GC acquires 1,299 ESPP shares

NovoCure Ltd General Counsel Ben Arye Barak acquired 1,299 ordinary shares through the company’s 2025 Employee Share Purchase Plan for the purchase period from January 1, 2026 through June 30, 2026.

Rhea-AI Filing Summary

NovoCure Ltd General Counsel Ben Arye Barak acquired 1,299 ordinary shares through the company’s 2025 Employee Share Purchase Plan for the purchase period from January 1, 2026 through June 30, 2026. The shares were purchased at 85% of the January 1, 2026 closing price, at a reported price of $11.15 per share, bringing his direct holdings to 243,752 shares.

Insider Trade Summary

Grant/Award: 1,299 shares

Grant/Award 1 txn

Insider Ben Arye Barak

Role General Counsel

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares	1,299	$11.15	$14K

Holdings After Transaction: Ordinary Shares — 243,752 shares (Direct)

Footnotes (2)

1. F1. The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2026 through June 30, 2026. This transaction is also exempt under Rule 16b-3(c).
2. F2. In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on January 1, 2026.

Key Figures

ESPP shares acquired: 1,299 shares Purchase price: $11.15 per share Holdings after transaction: 243,752 shares +1 more

4 metrics

ESPP shares acquired 1,299 shares Ordinary shares acquired on June 30, 2026 via 2025 ESPP

Purchase price $11.15 per share Price for ESPP acquisition of 1,299 ordinary shares

Holdings after transaction 243,752 shares Total direct NovoCure ordinary shares held after ESPP purchase

ESPP discount rate 85% of closing price Shares bought at 85% of January 1, 2026 closing price

Key Terms

Employee Share Purchase Plan, ESPP, Rule 16b-3(c), Form 4

4 terms

Employee Share Purchase Plan financial

"acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan ("ESPP")"

A program that lets employees buy their employer’s stock, often through regular payroll deductions and sometimes at a discounted price or with matching contributions; think of it as a company-run savings plan that converts part of pay into ownership. It matters to investors because it can increase insider ownership and employee motivation, potentially affecting company performance, and can slightly change share supply when new stock is issued or sold.

ESPP financial

"In accordance with the ESPP, these shares were purchased based on 85% of the closing price"

An Employee Stock Purchase Plan (ESPP) is a company program that lets employees buy the company’s shares at a reduced price, usually by setting aside a small portion of their pay over time. It matters to investors because it encourages employees to own part of the business—like giving staff a discounted membership— which can boost commitment and performance, while also potentially increasing the number of shares available and affecting shareholder value.

Rule 16b-3(c) regulatory

"This transaction is also exempt under Rule 16b-3(c)."

An SEC rule that lets corporate insiders avoid automatic "short‑swing" profit recovery when they buy or sell their company’s stock under a pre‑approved, written plan that meets specific conditions. For investors, it matters because it clarifies when insider trades are treated as routine, reducing legal uncertainty and helping distinguish trades made for ordinary compensation or pre‑planned reasons from those that might signal opportunistic or timely insider advantage.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did NovoCure (NVCR) report for Ben Arye Barak?

NovoCure reported that General Counsel Ben Arye Barak acquired 1,299 ordinary shares. The shares were obtained through the 2025 Employee Share Purchase Plan for the January 1, 2026 to June 30, 2026 purchase period, increasing his direct holdings to 243,752 shares.

How many NovoCure (NVCR) shares does Ben Arye Barak hold after this Form 4?

After the reported Employee Share Purchase Plan acquisition, Ben Arye Barak directly holds 243,752 NovoCure ordinary shares. This reflects the addition of 1,299 shares purchased under the 2025 ESPP during the January 1, 2026 to June 30, 2026 purchase period.

At what price were Ben Arye Barak’s NovoCure (NVCR) ESPP shares acquired?

The 1,299 NovoCure ordinary shares were acquired at $11.15 per share. Under the 2025 Employee Share Purchase Plan, these shares were purchased at 85% of the closing price of NovoCure’s ordinary shares on January 1, 2026, as described in the filing footnotes.

What is the 2025 NovoCure Employee Share Purchase Plan mentioned in the Form 4?

The 2025 NovoCure Employee Share Purchase Plan allows eligible employees to buy company shares, in this case for the January 1, 2026 to June 30, 2026 period. The filing notes shares were purchased at 85% of the January 1, 2026 closing price of NovoCure’s ordinary shares.

Is Ben Arye Barak’s NovoCure (NVCR) Form 4 transaction an open-market purchase?

No, the transaction is classified as a grant, award, or other acquisition under code A, via the 2025 Employee Share Purchase Plan. The shares were acquired at a discount formula tied to 85% of the January 1, 2026 closing price, not as an open-market trade.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/01/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ben Arye Barak

(Last) (First) (Middle)

C/O NOVOCURE INC.

1550 LIBERTY RIDGE DRIVE, SUITE 115

(Street)

WAYNE PENNSYLVANIA 19087

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NovoCure Ltd [ NVCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	06/30/2026		A	V	1,299	A	$11.15(2)	243,752	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2026 through June 30, 2026. This transaction is also exempt under Rule 16b-3(c).

2. In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on January 1, 2026.

Remarks:

	Steven Robbins, as attorney in fact for Ben Arye, Barak	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)